|10. In adults with active AS despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with tofacitinib.|Very low|61|
|11. In adults with active AS despite treatment with the first TNFi used, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with a different TNFi in patients with primary nonresponse to TNFi.|Low|8|